Search results
Results from the WOW.Com Content Network
Horse ointment, known as horse oil and horse fat, is a topical formulation derived from subcutaneous fat of horses. [1] Due to its thickness and viscosity , horse ointment is intended for topical use on human skin and mucous membranes to moisturize and increase the restoration of damaged skin.
The sternum and ileum contain the same quality of stem cells, but the ileum is usually harder to use in horses older than 5 years of age, because the marrow cavity shrinks. Marrow is collected using a Jamshidi needle in a sedated horse. Unlike people, horses usually tolerate the procedure well, with little pain.
Octreotate or octreotide acid is a somatostatin analogue that is closely related to octreotide. Its amino acid sequence is H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH while octreotide has the terminal threonine reduced to the corresponding amino alcohol.
It was approved for use in the United States in 1988. [2] [1] Octreotide was approved for medical use in the European Union in 2022. [4] As of June 2020, octreotide is the first oral somatostatin analog (SSA) approved by the FDA. [6] It is on the World Health Organization's List of Essential Medicines. [7]
Bone spavin indicated by A.. Bone spavin is osteoarthritis, or the final phase of degenerative joint disease (DJD), in the lower three hock joints.It usually affects the two lowest joints of the hock (the tarsometatarsal and the distal intertarsal joints), with the third joint, the proximal intertarsal, being the least likely to develop bone spavin.
As somatostatin can cause inhibition of hormone production that uses it as a mediating hormone, it has an antiproliferative effect on cell tumors, especially in neuroendocrine tumors. [2] Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative effects. [24]
However, any horse that can store excess amounts of glycogen, usually genetic, can develop this form of ER. [1] Recurrent Exertional Rhabdomyolysis (RER) is commonly found in breeds that are high strung such as Arabians and thoroughbreds. However, any horse can develop this type of ER if it displays abnormal muscle contractions. [1]
Ponazuril (), sold by Merial, Inc., [1] now part of Boehringer Ingelheim, [2] under the trade name Marquis (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.